Dyne Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| (in thousands) | 2024 | 2023 | 2022 |
| Cash flows from operating activities: | |||
| Net loss | $(317,418) | $(235,937) | $(168,099) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 45,864 | 19,972 | 15,178 |
| Depreciation and amortization expense | 1,673 | 1,673 | 1,683 |
| Amortization (accretion) of premium (discount) on marketable securities | (3,604) | (1,102) | 1,276 |
| (Gain) loss on sale of marketable securities | (35) | 23 | 34 |
| Non-cash lease expense | 570 | 788 | 1,662 |
| Loss on disposal of property and equipment | 72 | 118 | — |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (10,536) | 3,337 | (4,144) |
| Accounts payable and other liabilities | (8,955) | 22,970 | (1,235) |
| Net cash used in operating activities | (292,369) | (188,158) | (153,645) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (2,376) | (729) | (3,067) |
| Purchases of marketable securities | (317,443) | (44,262) | (121,176) |
| Maturities of marketable securities | 105,180 | 126,473 | 208,291 |
| Sales of marketable securities | 10,563 | 1,829 | 3,154 |
| Net cash (used in) provided by investing activities | (204,076) | 83,311 | 87,202 |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 675,180 | — | — |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 97,871 | 52,369 | 36,861 |
| Proceeds from exercise of stock options | 36,844 | 1,953 | 529 |
| Net cash provided by financing activities | 809,895 | 54,322 | 37,390 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 313,450 | (50,525) | (29,053) |
| Cash, cash equivalents and restricted cash, beginning of year | 123,941 | 174,466 | 203,519 |
| Cash, cash equivalents and restricted cash, end of year | $437,391 | $123,941 | $174,466 |
| Supplemental disclosures of cash flow information: | |||
| Purchase of property and equipment in accounts payable | $— | $12 | $85 |
| Proceeds from employee stock option exercise in other receivables | $199 | — | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.